司更色林 | 87729-89-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 司更色林
• 英文名称: 3-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
• 英文别名: Seganserin；3-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one
• CAS: 87729-89-3
• 化学式: C₂₉H₂₇F₂N₃O
• 分子量: 471.55
• InChiKey: ZGUPMFYFHHSNFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  35.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(双(4-氟苯基)亚甲基)哌啶 生成 司更色林
  参考文献：
  名称：

  KENNIS, L. E. J.;VANDENBERK, J.;MERTENS, J. C.

  摘要：

  DOI：

文献信息

• [EN] DEUTERATED LURASIDONE<br/>[FR] LURASIDONE DEUTÉRÉE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2018023009A1

  公开（公告）日：2018-02-01

  This invention relates to deuterated forms of hexahydro-4,7-methano-1H-isoindole-1,3(2H)-diones, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising a compound of this invention, including pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier. This invention also provides the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a compounds that modulates the activity of a receptor selected from the group consisting of central dopamine Type 2 (D2) receptor and serotonin Type 2 (5HT2A) receptor. Some exemplary embodiments include a method of treating a disease or condition selected from schizophrenia and depressive episodes associated with bipolar I disorder, the method comprising the step of administering to a subject in need thereof a pharmaceutically acceptable composition of the present invention.

  该发明涉及重氘化的六氢-4,7-甲基-1H-异吲哚-1,3(2H)-二酮及其药用盐。在一个方面，该发明提供了一种化合物的化学式(I)：或其药用盐。该发明还提供了包括该发明中的化合物的组合物，包括包含该化合物和药用载体的药物组合物。该发明还提供了在治疗通过给予调节中枢多巴胺2型（D2）受体和5-羟色胺2型（5HT2A）受体活性的化合物的方法中使用这些化合物和组合物。一些示例包括治疗精神分裂症和与I型双相情感障碍相关的抑郁发作的方法，该方法包括向有需要的受试者给予本发明的药用组合物。
• [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04485107A1

  公开（公告）日：1984-11-27

  Novel [[bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones, wherein the pyrimidinone-ring is embraced within a bicyclic system, being useful compounds in the treatment of psychosomatic disorders.

  [[双(芳基)亚甲基]-1-哌啶基]烷基嘧啶酮小说，其中嘧啶酮环被包含在一个双环系统内，是治疗心身疾病的有用化合物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04581171A1

  公开（公告）日：1986-04-08

  Novel [[bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones, wherein the pyrimidinone-ring is embraced within a bicyclic system, being useful compounds in the treatment of psychosomatic disorders.

  [[双(芳基)亚甲基]-1-哌啶基]烷基嘧啶酮的小说，其中嘧啶酮环被包含在一个双环系统中，是治疗心理身体疾病的有用化合物。
• New method for the detection of specific binding agents and their corresponding bindable substances
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0227173A2

  公开（公告）日：1987-07-01

  A method of qualitatively or quantitatively determining a component of a complex formed between at least one specific binding agent and its corresponding bindable substance. Said method comprises labelling at least one component of said complex with a marker which is easier to determine than the complex itself, whereby the marker used consists of latex particles which can be detected visually either by colour or fluorescence. Preferably the marker consists of coloured or colourable latex particles and the determination is based on the colour characteristics of the latex particles as such or, in the instance that colourable latex particles are used, on the colour characteristics of the coloured particles derived therefrom. The colour, respectively fluorescence signal is, if necessary after development, easily detected and optionally quantified. The invention further comprises coloured or colourable latex particles coated with specific binding proteins and test kits containing the same.

  一种定性或定量测定至少一种特异性结合剂与其相应的可结合物质之间形成的复合物的组分的方法。该方法包括用一种比复合物本身更容易确定的标记物对复合物中的至少一种成分进行标记，其中使用的标记物由可通过颜色或荧光目测的乳胶颗粒组成。标记物最好由有色或有色胶乳颗粒组成，根据胶乳颗粒本身的颜色特征来确定，或者在使用有色胶乳颗粒的情况下，根据由此产生的有色颗粒的颜色特征来确定。如有必要，可在显影后对颜色和荧光信号进行检测和量化。本发明还包括涂有特异性结合蛋白的有色或有色胶乳颗粒以及含有这些颗粒的检测试剂盒。